Weekly Scan · 15–21 June 2026 · No material signal change
China’s healthcare-policy calendar was quiet in the week of 15–21 June, a period that overlapped the Dragon Boat holiday. Nothing published in the window changes our standing read on intraocular-lens market access, pricing, or reimbursement.
Three items stay on the near-term watch list. First, the national volume-based procurement agreements for intraocular lenses reach the end of their two-year cycle at the end of June, Beijing on 28 June, the national second purchasing year on 30 June, and no lens-specific renewal or transitional notice has yet appeared, even though the device-procurement renewal mechanism is now visible from the recent coronary-stent round. Second, the ophthalmology grouping parameters for the 3.0 revision of case- and diagnosis-based payment are expected in the third quarter. Third, the domestic premium-lens field continues to consolidate.
None of these produced a binding instrument this week. We will publish when one does.
Key Implications
For market access and investment teams, the date that matters this fortnight is the end-June procurement-cycle expiry, not any single notice. Whether provinces extend existing results, open a national renewal, or leave a short execution gap is the variable to track into early July.
— The OphthalLogix Intelligence Team
For information only — not legal, regulatory, investment, or medical advice. Verify any regulatory development independently before acting. OphthalLogix Intelligence accepts no liability for reliance on this content. intelligence@ophthallogix.com · www.ophthallogix.com